CRAIG L. SLINGLUFF, M.D.
Radiology in Charlottesville, VA
License number
Virginia 0101046882
Category
Radiology
Type
Surgical Oncology
Address
Address
WEST The Cancer Ctr Hospital Dr, Charlottesville, VA 22908
Phone
(434) 924-1730
(434) 243-6844 (Fax)
(434) 243-6844 (Fax)
Personal information
See more information about CRAIG L. SLINGLUFF at radaris.comName
Address
Phone
256 Woodlands Rd, Charlottesvle, VA 22901
256 Woodlands Rd, Charlottesville, VA 22901
Norfolk, VA
256 Woodlands Rd, Charlottesville, VA 22901
1 Commercial Pl, Norfolk, VA 23510
Organization information
See more information about CRAIG L. SLINGLUFF at bizstanding.comSurgery-U Va - Craig L Slingluff MD
Hospital Dr #5443, Charlottesville, VA 22908
Categories:
General Surgeons, Oncology Physicians & Surgeons, Physicians & Surgeons
Site:
Phone:
(434) 924-1730 (Phone)
Professional information
See more information about CRAIG L. SLINGLUFF at trustoria.com
Dr. Craig L Slingluff - MD (Doctor of Medicine)
Dr. Craig L Slingluff - MD (Doctor of Medicine)
Hospitals:
Emily Couric Clinical Cancer Center
1240 Lee St, Charlottesville 22903
West Complex
1300 Jefferson Park Ave, Charlottesville 22903
University of Virginia Hospital
1215 Lee St, Charlottesville 22908
Emily Couric Clinical Cancer Center
1240 Lee St, Charlottesville 22903
West Complex
1300 Jefferson Park Ave, Charlottesville 22903
University of Virginia Hospital
1215 Lee St, Charlottesville 22908
1240 Lee St, Charlottesville 22903
West Complex
1300 Jefferson Park Ave, Charlottesville 22903
University of Virginia Hospital
1215 Lee St, Charlottesville 22908
Emily Couric Clinical Cancer Center
1240 Lee St, Charlottesville 22903
West Complex
1300 Jefferson Park Ave, Charlottesville 22903
University of Virginia Hospital
1215 Lee St, Charlottesville 22908
Education:
Medical Schools
Virginia Commonwealth University School Of Medicine
Graduated: 1984
Virginia Commonwealth University School Of Medicine
Graduated: 1984
Craig L Slingluff, Charlottesville VA
Craig L Slingluff, Charlottesville VA
Specialties:
Surgery, Surgical Oncology, Public Health & General Preventive Medicine
Work:
University of Virginia
PO Box 800709, Charlottesville, VA 22908 University of Virginia Physicians Group
Hospital Dr, Charlottesville, VA 22908
PO Box 800709, Charlottesville, VA 22908 University of Virginia Physicians Group
Hospital Dr, Charlottesville, VA 22908
Education:
University of Virginia (1984)
Peptides Recognized By Melanoma-Specific Cytotoxic Lymphocytes, And Uses Therefor
Peptides Recognized By Melanoma-Specific Cytotoxic Lymphocytes, And Uses Therefor
US Patent:
6660276, Dec 9, 2003
Filed:
Apr 29, 1994
Appl. No.:
08/234784
Inventors:
Craig L. Slingluff - Charlottesville VA
Victor M. Engelhard - Charlottesville VA
Donald F. Hunt - Charlottesville VA
Jeffrey Shabanowitz - Charlottesville VA
Andrea L. Cox - Charlottesville VA
Victor M. Engelhard - Charlottesville VA
Donald F. Hunt - Charlottesville VA
Jeffrey Shabanowitz - Charlottesville VA
Andrea L. Cox - Charlottesville VA
Assignee:
The University of Virginia Patent Foundation - Charlottesville VA
International Classification:
A61K 3900
US Classification:
4242771, 4241851, 514 14, 514 15
Abstract:
The instant disclosure identifies and synthesizes peptide residues initially isolated from a melanoma cell line. The peptides are capable of reconstituting an epitope recognized by tumor specific CTL. Some of the sequences are homologous with proteins identified as pMEL17, tyrosinase and cofilin. The present invention provides for the treatment of melanoma patients using synthetic peptides that reconstitute epitopes for melanoma specific CTL. In another embodiment the peptides are used as vaccines for imparting immunity. Alternatively, in one embodiment the peptides may be used to bind to antigen presenting cells in a method for providing specific antigenic stimulation of CTL. The instant invention provides CTL cell lines capable of recognizing reconstituted HLA-A2. 1 epitopes and their use in methods of adoptive immunotherapy. The invention additionally provides for genes encoding for peptides capable of reconstituting epitopes recognized by tumor specific CTL and their use as vaccines in the prevention and management of melanoma.
Cysteine-Depleted Peptides Recognized By A3-Restricted Cytotoxic Lymphocytes, And Uses Therefor
Cysteine-Depleted Peptides Recognized By A3-Restricted Cytotoxic Lymphocytes, And Uses Therefor
US Patent:
6558671, May 6, 2003
Filed:
Sep 20, 1999
Appl. No.:
09/341982
Inventors:
Craig L. Slingluff - Charlottesville VA
Donald F. Hunt - Charlottesville VA
Victor H. Engelhard - Charlottesville VA
David Kittlesen - Charlottesville VA
Donald F. Hunt - Charlottesville VA
Victor H. Engelhard - Charlottesville VA
David Kittlesen - Charlottesville VA
Assignee:
The University of Virginia Patent Foundation - Charlottesville VA
International Classification:
A61K 3900
US Classification:
4241851, 4241841, 4241931, 435 71, 435 724, 4351734, 4351737, 530300, 530326, 530327, 530328, 530403
Abstract:
Cysteine-depleted CTL epitopes can elicit a stronger or more specific CTL response than the native, cysteine-containing CTL epitope of a disease associated antigen.
Tag-1 And Tag-2 Proteins And Uses Thereof
Tag-1 And Tag-2 Proteins And Uses Thereof
US Patent:
2006014, Jun 29, 2006
Filed:
Jul 1, 2004
Appl. No.:
10/561339
Inventors:
Kevin Hogan - Charlottesville VA, US
Craig Slingluff - Charlottesville VA, US
Craig Slingluff - Charlottesville VA, US
International Classification:
A61K 39/395, C12Q 1/68, G01N 33/574, C07H 21/04, C12P 21/06, C07K 14/82, C07K 16/30
US Classification:
424155100, 435006000, 435007230, 435069100, 435320100, 435325000, 530350000, 530388800, 536023500
Abstract:
The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of cancer and/or used in therapeutics to treat cancer.
Peptides Recognized By Melanoma-Specific A1-, A2- And A3-Restricted Cytoxic Lymphocytes, And Uses Therefor
Peptides Recognized By Melanoma-Specific A1-, A2- And A3-Restricted Cytoxic Lymphocytes, And Uses Therefor
US Patent:
7019112, Mar 28, 2006
Filed:
Mar 12, 1997
Appl. No.:
08/816454
Inventors:
Craig L. Slingluff - Charlottesville VA, US
Donald F. Hunt - Charlottesville VA, US
Jeffrey Shabanowitz - Charlottesville VA, US
Andrea L. Cox - Charlottesville VA, US
Victor H. Engelhard - Charlottesville VA, US
David Kittlesen - Charlottesville VA, US
Jonathan Skipper - Oxford, GB
Ronald C. Hendrikson - Seattle WA, US
Donald F. Hunt - Charlottesville VA, US
Jeffrey Shabanowitz - Charlottesville VA, US
Andrea L. Cox - Charlottesville VA, US
Victor H. Engelhard - Charlottesville VA, US
David Kittlesen - Charlottesville VA, US
Jonathan Skipper - Oxford, GB
Ronald C. Hendrikson - Seattle WA, US
Assignee:
University of Virginia Patent Foundation - Charlottesville VA
International Classification:
C07K 7/06
US Classification:
530328
Abstract:
Melanoma-specific, A1- and A3-restricted CTL epitopes have been identified in tyrosinase and pMel-17, respectively, and may be used in the design of vaccines.